Organon & Co. (OGN) to Issue Quarterly Dividend of $0.02 on March 12th

Organon & Co. (NYSE:OGN) announced a quarterly dividend on Thursday, February 12th. Investors of record on Monday, February 23rd will be paid a dividend of 0.02 per share on Thursday, March 12th. This represents a c) dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Monday, February 23rd.

Organon & Co. has a dividend payout ratio of 2.0% indicating that its dividend is sufficiently covered by earnings. Analysts expect Organon & Co. to earn $3.74 per share next year, which means the company should continue to be able to cover its $0.08 annual dividend with an expected future payout ratio of 2.1%.

Organon & Co. Price Performance

Shares of NYSE:OGN opened at $7.38 on Friday. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69. The firm has a market capitalization of $1.92 billion, a PE ratio of 10.40, a P/E/G ratio of 1.53 and a beta of 0.58. Organon & Co. has a twelve month low of $6.18 and a twelve month high of $16.50. The company has a 50-day moving average price of $7.89 and a two-hundred day moving average price of $8.59.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.73 by ($0.10). The business had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.52 billion. Organon & Co. had a net margin of 3.01% and a return on equity of 123.06%. The business’s revenue for the quarter was down 5.3% on a year-over-year basis. During the same period last year, the firm earned $0.90 EPS. Equities analysts forecast that Organon & Co. will post 3.68 EPS for the current year.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.